• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Assembly Biosciences Inc.

    4/23/25 4:18:42 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASMB alert in real time by email
    DEFA14A 1 2025-04-23_defa14a.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934 (Amendment No. )

     

    ☒

    Filed by the Registrant

     

    ☐

    Filed by a party other than the Registrant

     

    CHECK THE APPROPRIATE BOX:

     

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under § 240.14a‑12

     

    img246773697_0.jpg

     

    Assembly Biosciences, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

     

    PAYMENT OF FILING FEE (CHECK ALL BOXES THAT APPLY):

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     


     

    img246773697_1.jpg

    Assemblybio Your Vote Counts! ASSEMBLY BIOSCIENCES, INC. 2025 Annual Meeting Vote by June 4, 2025 11:59 PM EDT ASSEMBLY BIOSCIENCES, INC. TWO TOWER PLACE, 7TH FLOOR SOUTH SAN FRANCISCO, CA 94080 V65646-P26884 You invested in ASSEMBLY BIOSCIENCES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 5, 2025. Vote Virtually at the Meeting* June 5, 2025 8:00 A.M. PDT Virtually at: www.virtualshareholdermeeting.com/ASMB2025 Get informed before you vote View the Notice of Assembly Biosciences, Inc.’s 2025 Annual Meeting of Stockholders and Proxy Statement and Annual Report for the fiscal year ended December 31, 2024 online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 5, 2025 8:00 A.M. PDT Virtually at: www.virtualshareholdermeeting.com/ASMB2025 *Please check the meeting materials for any special requirements for meeting attendance.


     

    img246773697_2.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items Board Recommends V65647-P26884 1. Election of Directors. Nominees: 1a. William R. Ringo, Jr. For 1b. Anthony E. Altig For 1c. Tomas Cihlar, Ph.D. For 1d. Gina Consylman For 1e. Robert D. Cook II For 1f. Sir Michael Houghton, Ph.D. For 1g. Lisa R. Johnson-Pratt, M.D. For 1h. Susan Mahony, Ph.D. For 1i. John G. McHutchison, A.O., M.D. For 1j. Jason A. Okazaki For 2. Approval, on a non-binding advisory basis, of our named executive officers’ compensation. For 3. Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. For 4a. Approval of an amendment to our Amended and Restated 2018 Stock Incentive Plan to increase the number of shares reserved for issuance thereunder by 375,000 shares. For 4b. Approval of an additional amendment to our Amended and Restated 2018 Stock Incentive Plan to increase the number of shares reserved for issuance thereunder by 225,000 shares to support a broad-based supplemental retention grant program. For 5. Approval of an amendment to our Second Amended and Restated 2018 Employee Stock Purchase Plan to increase the authorized number of shares reserved for issuance thereunder to 225,000 shares. For NOTE: Your proxy holder will also vote in their discretion upon such other matters that may properly come before the meeting and any adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.


    Get the next $ASMB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ASMB

    DatePrice TargetRatingAnalyst
    3/25/2025$31.00Buy
    Guggenheim
    9/20/2024$2.00 → $35.00Hold → Buy
    Jefferies
    9/13/2021$3.50Neutral
    HC Wainwright & Co.
    9/2/2021Outperform → Market Perform
    William Blair
    More analyst ratings

    $ASMB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

      – Study will evaluate safety and antiviral activity of ABI-1179 in participants with recurrent genital herpes – – ABI-1179 IND cleared to support study expansion to sites in United States – – Phase 1b studies for ABI-1179 and ABI-5366 running concurrently with interim data for both candidates on track for fall 2025 – SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b portion of the Phase 1a/b study of its long-acting herpes simplex virus (HSV) helicase-primase inhibitor

      6/30/25 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

      – Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be observed in final 400 mg cohort – – Mean plasma HBV DNA reductions of 3.2 logs IU/mL over 28 days of treatment for 400 mg cohort consistent with findings in 150 mg cohort, supporting ability of 150 mg dose to achieve saturated inhibition of viral replication, as anticipated – – Trial completion triggers opt-in point under collaboration with Gilead Sciences, Inc. following delivery and review of option data package – SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovativ

      6/25/25 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and Anuj Gaggar, MD, PhD, chief medical officer, will present in a fireside chat during the Jefferies 2025 Global Healthcare Conference at 8:45 a.m. Eastern Time on June 4, 2025. A live webcast will be available on the Events and Presentations section of Assembly Bio's website and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/eve

      5/27/25 4:05:00 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PFO and PAO Bjorkquist Jeanette M was granted 300 shares, increasing direct ownership by 6% to 5,097 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      6/17/25 4:05:04 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Houghton Michael

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      6/9/25 4:05:21 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Mahony Susan

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      6/9/25 4:05:19 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Assembly Biosciences Inc.

      SC 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      11/14/24 3:22:29 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

      SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      6/24/24 4:28:09 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

      SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

      6/20/24 8:35:37 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASMB
    SEC Filings

    See more
    • Assembly Biosciences Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      6/25/25 4:05:30 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      6/9/25 5:00:14 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Assembly Biosciences Inc.

      10-Q - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Filer)

      5/8/25 4:15:34 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Guggenheim initiated coverage on Assembly Biosciences with a new price target

      Guggenheim initiated coverage of Assembly Biosciences with a rating of Buy and set a new price target of $31.00

      3/25/25 8:26:24 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences upgraded by Jefferies with a new price target

      Jefferies upgraded Assembly Biosciences from Hold to Buy and set a new price target of $35.00 from $2.00 previously

      9/20/24 7:32:14 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Assembly Biosciences with a new price target

      HC Wainwright & Co. initiated coverage of Assembly Biosciences with a rating of Neutral and set a new price target of $3.50

      9/13/21 6:42:05 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASMB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Houghton Michael bought $49,998 worth of shares (3,202 units at $15.61) (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      12/31/24 4:24:14 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Gilead Sciences, Inc. bought $20,098,464 worth of shares (940,499 units at $21.37), increasing direct ownership by 74% to 2,209,471 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      12/23/24 8:26:39 PM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Schornstein Alexander bought $371,994 worth of shares (25,000 units at $14.88), increasing direct ownership by 4% to 728,113 units (SEC Form 4)

      4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

      11/26/24 9:15:02 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASMB
    Leadership Updates

    Live Leadership Updates

    See more
    • Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

      -- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C vi

      11/8/23 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

      −ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program. 5366 is the first development candidate from Assembly Bio's discovery pipeline nominated for adv

      2/15/23 8:00:00 AM ET
      $ASMB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

      Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde

      1/17/23 7:00:00 AM ET
      $ASMB
      $PRDS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products